newsfilter
← Latest News
GlobeNewswire·

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

  • Enlivex Ltd. received a Nasdaq delisting notice dated October 26, 2026, due to its ordinary shares failing to maintain a $1.00 minimum bid price for 30 consecutive business days.
  • The company is ineligible for the standard 180-day compliance period because it executed a reverse share split within the preceding 12 months.
  • Enlivex plans to appeal the decision by requesting an oral hearing before the Nasdaq Hearings Panel under Listing Rule 5815.
  • The appeal request will stay any suspension or delisting action pending the hearing, allowing shares to continue trading on the Nasdaq Capital Market.
  • The company cannot guarantee the appeal's success or that its shares will remain listed following the hearing.
  • To support the appeal & regain compliance, Enlivex implemented a 1-for-16 reverse split of its ordinary shares effective October 27, 2026.
  • Enlivex is a longevity company developing Allocetra™ for age-related osteoarthritis & operates a prediction markets treasury using the Rain protocol on Arbitrum.